Please login to the form below

Not currently logged in
Email:
Password:

Minoyrx Therapeutics appoints chief medical officer

Dr Uwe Meya joins from Lupin Atlantis Holdings

Minoryx Therapeutics Dr Uwe MeyaSpanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer.

Dr Meya brings over 30 years of research and development experience to the firm, with a background as a neurologist and psychiatrist.

He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders.

Prior to this, Dr Meya was head of phase I and II clinical studies in neurodegenerative disorders at Synosia Therapeutics, and served as head of research portfolio management and clinical research and licensing liaison manager in CNS at Roche.

He also has leadership experience working at Novartis in CNS clinical development, at Knoll as head of clinical development, and as a medical advisor and the head of clinical psychiatry at Schering.

Marc Martinell, chief executive officer of Minoryx Therapeutics, said: “We are delighted to welcome Dr Meya as our chief medical officer.

“Hi wealth of expertise in CNS-related research will help us significantly in moving forward the clinical development of our lead candidate MIN-102. He will also support the further development of our pipeline in orphan diseases.”

24th June 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics